Thymosin Alpha-1

What It Is

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally produced by the thymus gland that plays a central role in T-cell maturation, dendritic cell activation, and innate immune regulation. The synthetic version — thymalfasin, marketed as Zadaxin — is approved in over 35 countries for the treatment of hepatitis B, hepatitis C, and as an immune adjuvant in cancer therapy. It is one of the most clinically validated immune-modulating peptides in existence, with data from over 4,400 patients across more than 80 clinical trials spanning hepatitis, HIV adjunct therapy, cancer immunotherapy, sepsis, vaccine enhancement, and primary immunodeficiency disorders. Thymosin Alpha-1 enhances immune function by promoting T-cell differentiation, stimulating natural killer (NK) cell activity, and modulating cytokine production to shift immune responses toward a Th1-dominant profile. In oncology, it is being evaluated as a 'primer' for checkpoint immunotherapy: as of early 2026, at least three active Phase II trials are testing Thymosin Alpha-1 before or alongside anti-PD-1/PD-L1 therapy in hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), and gastric cancer. Its safety profile is well-established, with Grade 3–4 adverse events occurring in fewer than 5% of trial participants, primarily injection-site reactions and rare hypersensitivity responses. In the United States, Thymosin Alpha-1 was returned to Category 1 compounding eligibility under the FDA's February 2026 reclassification announcement by HHS Secretary Robert F. Kennedy Jr. This means it may be compounded by licensed 503A/503B pharmacies under physician prescription, though it remains unapproved by the FDA as a drug product. It is not available over the counter and requires medical supervision for use.

Regulatory Status

Why Researchers Study It

Thymosin Alpha-1 is studied because of its broad, well-documented immunomodulatory effects and its established safety record across thousands of patients in controlled trials. Its ability to enhance both innate and adaptive immunity — particularly T-cell and NK cell function — makes it relevant to cancer immunotherapy, chronic viral infections, sepsis management, and vaccine adjuvant research. The 2026 FDA reclassification has renewed interest in its clinical applications within the United States.

Proposed Mechanisms

• Promotes differentiation and maturation of T-cells from thymic progenitors
• Stimulates natural killer (NK) cell cytotoxic activity
• Activates dendritic cells and enhances antigen presentation
• Modulates cytokine profiles, shifting toward Th1-dominant immune responses
• Upregulates toll-like receptors (TLR2, TLR9), enhancing innate pathogen recognition
• May enhance efficacy of checkpoint inhibitors (anti-PD-1/PD-L1) by priming the tumor microenvironment

Evidence Snapshot

Commonly Discussed Benefits

Safety & Cautions

Comparisons

See how Thymosin Alpha-1 compares to related peptides:

Calculator Tools

Use our research tools to explore dosing and reconstitution data:

Citations

1. [1] Tuthill C. et al. — Thymosin alpha 1: past clinical experience and future promise. Ann N Y Acad Sci. 2010 PubMed
2. [2] Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials — PubMed 2024 PubMed
3. [3] Thymosin Alpha-1 Clinical Trials 2026 — Real Peptides PubMed

Related Peptides